-
Wuxi Biologics
TOPIC
 / company

Wuxi Biologics

Wuxi Biologics
Wuxi Biologics
Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province. It counts 16 of the world's top 20 drug makers as customers and 28 of China's 50 largest medicine producers. The company supplied ingredients for AstraZeneca's Covid-19 vaccine. It is one of six businesses founded by its chairman Ge Li, along with Wuxi Apptec.
Chairman / President
Li Ge
CEO / Managing Director
Chen Zhisheng
CFO / Finance Director
Tu Ming
Industry
Biopharmaceutical
Website
wuxibiologics.com.cn
Headquarters address
No. 108 Mashan Meiliang Road, Binhu Distroct, Wuxi City, Jiangsu Province, China
Stock Code
SEHK:2269
Year founded
2010
LATEST China Science NEWS

China’s chip breakthrough, Tang Dynasty armour restored: 7 science highlights

A fibre integrated circuit is a novel electronic device that is as thin as a strand of human hair. Photo: Handout

Chinese drug could help India’s Nipah virus surge: Wuhan Institute of Virology

videocam
9
Researchers from the Wuhan Institute of Virology found that the drug increased survival rates among hamsters. Photo: AFP

Composite tool find puts China in tech revolution up to 160,000 years ago: paper

A new paper published in Nature Communications says the presence of hafted stone tools among discoveries in China shows “an understanding of how to enhance tool performance”. Image: Handout

Chinese satellite forces 4,400 of its Starlink rivals into lower altitude: study

27
SpaceX has said it will move thousands of its internet satellites into a lower orbit. Photo: SpaceX

China could approve first AI-designed drug next year, Merck executive says

AI will allow drug makers to pick better molecules, make better medicines and improve molecule design, Amgen executive says. Photo: Shutterstock
MORE China Science NEWS
Global investors have reaped sizeable rewards from their investments in Hong Kong-listed biotech and pharmaceutical companies in the past year. Photo: Shutterstock
Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

Hong Kong stock market

Hong Kong stocks climb as yuan strengthens and investors broaden focus beyond US

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

Science

Why US lawmakers killed a proposal targeting science efforts with China

US researchers and industry experts warn that even the revised version may have unintended consequences.

videocam
11
A US defence bill, now awaiting President Donald Trump’s signature, includes new restrictions aimed at the medical industry and supply chains, blocking federal funds from going to biotechnology companies linked to so-called adversaries. Photo: Reuters
China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Shanghai

China bets on bio-manufacturing as new growth engine, bid for tech self-reliance

The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

Ignore China’s innovation boom ‘at your own peril’, General Atlantic CEO warns

Easing of US-China tensions and strong Hong Kong equity market present new opportunities, William Ford says at the Family Business Summit.

General Atlantic chairman and CEO William Ford at the Rosewood Hotel in Hong Kong on November 6. Photo: Jonathan Wong
Hong Kong stock market

Hong Kong stocks post longest decline in 9 months on renewed US-China tensions

Markets react to Trump’s threat to impose a 100 per cent tariff on all Chinese imports and restrict critical software exports from November.

Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

Hong Kong stock market

Hong Kong stocks cap weekly decline on valuation, tariff jitters

‘Gravity has reasserted itself’ and the global US$15 trillion rebound this year ‘now feels stretched’, investor says.

A view of Exchange Square in Central on April 7, 2025. Photo: Jelly Tse
Hong Kong stock market

Chinese biotechs get a shot in the arm from policy support, licensing deals

‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.

Shares of WuXi Biologics have more than doubled year to date. Photo: Shutterstock
Biomedicine: Companies

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says

MGI’s latest product, the DNBSEQ-T7+, can sequence 144 human genomes a day, or one every 10 minutes.

Hong Kong stock market

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

The Trump administration has been discussing severe restrictions on medicines from China, according to The New York Times.

Hong Kong stock market

Alibaba surge leads Hong Kong stocks to biggest gain in 2 weeks

Hong Kong stocks are undervalued, and a ‘liquidity friendly environment’ is set to propel them higher, analyst says.

Exchange Square in Central, Hong Kong, home of the city’s bourse operator, is pictured on May 20, 2025. Photo: Xinhua
Hong Kong stock market

Hong Kong stocks rebound on US-China trade talk optimism

Hang Seng Index recovers from an intraday loss of as much as 0.9 per cent, snapping a four-day losing streak.

People walk past an electronic board showing the Hang Seng Index in Hong Kong. Photo: Zuma Press Wire/dpa
Hong Kong stock market

Hong Kong stocks sustain 3-year-high level on trade optimism

A US deal with Japan and scheduled talks with China reduce concerns about damage to the global economy from trade conflicts.

Hong Kong stock market

Hong Kong stocks cap weekly gain on earnings optimism

Wuxi AppTec jumps after it says its first-half profit likely more than doubled from a year earlier.

Advertisement
Advertisement
Advertisement
Hong Kong stock market

Hong Kong stocks gyrate amid Iran conflict after US strike, Hormuz threat

Oil futures surge after US President Donald Trump says attacks ‘obliterated’ targets and Iran threatens to close key oil shipping route.

Oil tankers pass through the Strait of Hormuz in a 2018 file photo. Photo: Reuters
Hong Kong stock market

Hong Kong stocks rise on China policy hopes after soft economic data

China’s industrial output and fixed-asset investment fell short in May, and the downturn in the property market deepened.

Hong Kong stock market

Hong Kong stocks erase gains amid ongoing US-China trade talks

Investors appear to look more cautiously at ongoing US-China trade talks in London.

Hong Kong stock market

Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade

Hang Seng Index approached a two-month high on bets global trade relations and market sentiment will improve.

videocam
A screen showing the Hang Seng Index in HKEX Connect Hall in Central. Photo: Sun Yeung
Hong Kong stock market

Hong Kong stocks gain on earnings boost as Meituan beats market consensus

Gains limited by losses in leading carmakers amid lingering concerns about a prolonged price war.

videocam
Exchange Square in Central. Hong Kong. Photo: Sam Tsang
Biomedicine: Companies

Big Chinese pharma can beat Trump’s policies with cost efficiencies: analysts

Trump seeks to slash domestic drug prices, bring back pharmaceutical manufacturing to the US and slap tariffs on imports.

videocam
China Future Tech briefing

Biomedicine | China’s biomedical sector braces for headwinds

The coast isn’t entirely clear for the world’s second-largest biomedical sector, which faces possible tariff increases and US import curbs.

Biomedicine: Companies

China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

WuXi Biologics company logo. Photo: Shutterstock
Biomedicine: Companies

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

The bill’s absence from the proposed amendments to the US National Defence Authorisation Act comes as a reprieve for the two biotech firms.

WuXi AppTec says it provides US lawmakers and federal agencies with information about the services it provides to customers in the US and around the world. Photo: Shutterstock
Biomedicine: Policy

Shanghai to back local biopharma firms’ overseas push, regulatory compliance

The initiative aims to generate about US$7 billion from medical product exports by 2027.

videocam
Wuxi AppTec

WuXi AppTec, WuXi Biologics rise in Hong Kong as some operations go up for sale

The gains were made on the back of a report that said the two firms plan to sell certain overseas operations amid heightened US scrutiny.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement